Klinisk Biokemi i Norden Nr 1, vol. 32, 2020 - page 10

10 | 
Klinisk Biokemi i Norden · 1 2020
Nordic Congress in Medical Biochemistry,
9-12 June, 2020, Trondheim, Norway
(Preliminary scientific program and confirmed speakers as of 10.01.2020)
Please note that order and title of sessions, keynotes and lectures may change. (TBA: to be announced)
Day 1 June 9
15:00 - 18:00
OPENING CEREMONY
Keynote: Menno P. Witter
(Kavli Institute for Systems Neuroscience, Norwegian University of Science and
Technology)
Neuronal specificity and neurodegenerative diseases. A special case for the entorhinal cortex
and Alzheimer’s disease.
THE ASTRUP PRIZE COMPETITION 2020
Day 2 June 10
08:30 – 17:10
Keynote: Dennis Lo
(The Chinese University of Hong Kong)
Plasma DNA-based molecular diagnostics:
fragments, circles and beyond.
PARALLEL SESSION 1
PARALLEL SESSION 2
PARALLEL SESSION 3
Neurological disease markers
• K Blennow
(Sweden) Measure-
ment and clinical utility of CSF
proteins
• M Christiansen
(Denmark)
CSF kappa light chains for MS
diagnosis
• J
Posti
(Finland) Biomarkers of
traumatic brain injury
• J Kuhle
(Switzerland) Blood neu-
rofilament light chain: ready for
the clinic?
The quality of POCT
• R Keller
(Germany) A unified
system for quality control of POC
instruments in a big hospital
setting
• N Sørensen
(Denmark) Point-
of-care testing of troponin in
suspected myocardial infarction
• A Stavelin
(Norway) Ensuring
quality of POCT in primary
healthcare
• S Sandberg
(Norway) New trends
in point of care testing
Clinical utility of genomics
• A Palotie
(Finland) GWAS, WES
and its likes
• K Hveem
(Norway) GWAS of
70 000 individuals in the HUNT
study: clinically relevant findings
• K Pantel
(Germany) The clinical
impact of liquid biopsy/cfDNA,
ctDNA
• O Spigset
(Norway) Pharmacoge-
netics in clinical practice: useful
tool or overrated and unnecessary?
Lunch Break
Keynote: Fred Apple
(University of Minnesota School of Medicine)
Troponin in early diagnostics and risk
assessment.
PARALLEL SESSION 4
PARALLEL SESSION 5
PARALLEL SESSION 6
Emerging analytical technologies
• A van den Berg
(The Nether-
lands) Small means gone - mov-
ing analytics away from the lab to
a chip and beyond
• H Zetterberg
(Sweden) Ultra-
sensitive technologies to measure
biomarkers for CNS disease in
blood
• U Landegren
(Sweden) Proxim-
ity extension and –ligation assay
technologies
• E S Husebye
(Norway) ULTRA-
DIAN - dynamic hormone diag-
nostics
Inborn errors of metabolism
• A Wedell
(Sweden) An integrated
approach for precision diagnostic
of inborn errors of metabolism
• Y T Bliksrud
(Norway) Diagnos-
ing inborn errors of metabolism
• R Lapatto
(Finland) Clinician’s
wishes
• L
Franzson
(Iceland) Are rare
diseases rare?
Cardiac troponins in the non-acute
setting
• S Blankenberg
(Germany) Tro-
ponin screening in the general
population or in targeted high-
risk populations: will it improve
outcome?
• S Ørn
(Norway) Is it possible to
differentiate between a physiolog-
ical and a pathological troponin
elevation?
• S Meex
(The Netherlands) Meas-
urement of circulating troponin
fragments – analytical concerns
and clinical implications
• T Omland
(Norway) Biomarker
testing to predict cardiotoxicity
following cancer treatment
1,2,3,4,5,6,7,8,9 11,12,13,14,15,16,17,18,19,20,...40
Powered by FlippingBook